Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Signs Of Long-Term Efficacy Boost UniQure’s Hem B Gene Therapy

Will Await Main Study’s One-Year Milestone Before Submission

Executive Summary

Unveiling its latest data, UniQure is tipped to avoid the knockback which affected BioMarin’s hemophilia A gene therapy, with a filing expected in the second half of 2021.

You may also be interested in...



UniQure Needs Longer-Term Data For Hemophilia B Gene Therapy EtranaDez

The FDA may want longer follow-up data for companies developing treatments for hemophilia A as well as hemophilia B.

Relief For UniQure Hemophilia Program Sends Ball To FTC’s Court

While anticipated, the removal of the hold on uniQure’s hemophilia B program removes significant overhang, as the focus shifts to an anticipated FTC antitrust clearance of its CSL Behring deal.

UniQure Expects To Resolve FDA Clinical Hold Within Three Months

The gene therapy EtranaDez for hemophilia B placed on clinical hold after a patient was diagnosed with liver cancer, but UniQure points to that patient’s extensive history of liver disease.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143450

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel